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Abstract: CONTEXT Unilateral adrenalectomy has been proposed in selected patients with primary
bilateral macronodular adrenocortical hyperplasia (PBMAH), but its long-term outcome is unclear. OB-
JECTIVE The aim of this study was to analyze long-term clinical and biochemical outcome of unilateral
adrenalectomy versus bilateral adrenalectomy in patients with PBMAH in comparison to outcome of
cortisol-producing adenoma (CPA) treated by unilateral adrenalectomy. DESIGN Retrospective ob-
servational study in three German and one Italian academic tertiary care center. PATIENTS AND
METHODS 25 PBMAH patients after unilateral adrenalectomy (unilat-ADX-PBMAH), 9 patients with
PBMAH and bilateral adrenalectomy (bilat-ADX-PBMAH) and 39 patients with CPA and unilateral
adrenalectomy (unilat-ADX-CPA) were included. RESULTS Baseline clinical and biochemical parame-
ters were comparable in unilat-ADX-PBMAH, bilat-ADX-PBMAH and unilat-ADX-CPA. Directly after
surgery, 84% of the unilat-ADX-PBMAH patients experienced initial remission of Cushing’s syndrome.
In contrast, at last follow-up (median 50 months) 32% of the unilat-ADX-PBMAH patients were bio-
chemically controlled compared to nearly all patients in the other two groups (p=0.000). Adrenalectomy
of the contralateral side had to be performed in 12% of the initially unilat-ADX-PBMAH patients. 3 of
20 unilat-ADX-PBMAH patients (15%) died during follow-up presumably of Cushing’s syndrome related
causes whereas no deaths occurred in the other two groups (p=0.008). Deaths occurred exclusively in
patients who were not biochemically controlled after unilateral ADX. CONCLUSIONS Our data suggest
that unilateral adrenalectomy of PBMAH patients leads to clinical remission and a lower incidence of
adrenal crisis, but less sufficient biochemical control of hypercortisolism potentially provoking a higher
mortality.
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CONTEXT 
Unilateral adrenalectomy has been proposed in selected patients with primary bilateral 
macronodular adrenocortical hyperplasia (PBMAH), but its long-term outcome is unclear. 
OBJECTIVE 
The aim of this study was to analyze long-term clinical and biochemical outcome of 
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comparison to outcome of cortisol-producing adenoma (CPA) treated by unilateral 
adrenalectomy. 
DESIGN 
Retrospective observational study in three German and one Italian academic tertiary care 
center.  
PATIENTS AND METHODS 
25 PBMAH patients after unilateral adrenalectomy (unilat-ADX-PBMAH), 9 patients with 
PBMAH and bilateral adrenalectomy (bilat-ADX-PBMAH) and 39 patients with CPA and 
unilateral adrenalectomy (unilat-ADX-CPA) were included. 
RESULTS 
Baseline clinical and biochemical parameters were comparable in unilat-ADX-PBMAH, 
bilat-ADX-PBMAH and unilat-ADX-CPA. Directly after surgery, 84% of the unilat-ADX-
PBMAH patients experienced initial remission of Cushing’s syndrome. In contrast, at last 
follow-up (median 50 months) 32% of the unilat-ADX-PBMAH patients were biochemically 
controlled compared to nearly all patients in the other two groups (p=0.000). Adrenalectomy 
of the contralateral side had to be performed in 12% of the initially unilat-ADX-PBMAH 
patients. 3 of 20 unilat-ADX-PBMAH patients (15%) died during follow-up presumably of 
Cushing’s syndrome related causes whereas no deaths occurred in the other two groups 
(p=0.008). Deaths occurred exclusively in patients who were not biochemically controlled 
after unilateral ADX.  
CONCLUSIONS 
Our data suggest that unilateral adrenalectomy of PBMAH patients leads to clinical remission 
and a lower incidence of adrenal crisis, but less sufficient biochemical control of 
hypercortisolism potentially provoking a higher mortality.  
Unilateral adrenalectomy in primary bilateral macronodular adrenocortical hyperplasia leads to a lower 
rate of adrenal insufficiency, but also less sufficient biochemical control of hypercortisolism. 
Main Text 
INTRODUCTION 
Endogenous Cushing’s syndrome (CS) is a severe disease based on excessive glucocorticoid 
production 1. In approximately 20% of cases cortisol is secreted autonomously by the adrenal 
cortex 2. Adrenal Cushing’s syndrome is mostly caused by unilateral cortisol-producing 
adrenal adenomas (CPA) and less frequently by cortisol-secreting carcinomas. Very rare 
causes are primary bilateral macronodular adrenocortical hyperplasia (PBMAH), bilateral 
CPAs and primary pigmented micronodular adrenal disease 3,4.  
PBMAH presents on imaging with a characteristic appearance of multiple bilateral 
macronodules (>10 mm) with hyperplasia and/or internodular atrophy 5. 
Pathophysiologically, the expression of aberrant membrane receptors in the adrenal cortex 
plays an important role 4. In most instances, PBMAH is a sporadic disorder, although familial 
cases have been described 6. Biallelic inactivating variants in the Armadillo repeat containing 
5 gene (ARMC5), a tumor suppressor gene, is a frequent cause of PBMAH 7. 
Characteristically, a germline and a somatic tissue-specific gene variant are required for the 
development of PBMAH, which is consistent with the two-hit hypothesis of tumorigenesis 8.  
Treatment of choice to control hypercortisolism in patients with PBMAH is bilateral 
adrenalectomy, which inevitably results in lifelong glucocorticoid dependence and, thereby, 
risk of adrenal crisis 6. To avoid the induction of adrenal insufficiency, resection of only one 
adrenal gland has been advocated. Indeed, several recent studies have reported clinical and 
biochemical improvement after unilateral adrenalectomy 9-13. However, the number of 
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series of PBMAH patients following unilateral adrenalectomy with analysis of long-term 
results regarding biochemical and clinical outcomes as well as morbidity and mortality. We 
compare their outcome to PBMAH patients treated by bilateral adrenalectomy and to CPA 
patients treated by unilateral adrenalectomy. 
Subjects and Methods 
Patient cohorts 
Patients with adrenal Cushing’s syndrome were recruited in four European academic tertiary 
centers (Medizinische Klinik IV, Munich (n=52), Endocrinology in Charlottenburg, Berlin 
(n=15), S. Orsola-Malpighi Hospital, Bologna (n=10) and Division of Endocrinology and 
Diabetes, Department of Internal Medicine I, University Hospital Würzburg (n=8)). German 
patients were asked to participate in a long-term evaluation within the German Cushing’s 
Registry CUSTODES 14.  
Diagnosis was confirmed by chart review with special focus on histology and radiology. 
All adrenal scans were reviewed in a multidisciplinary tumor board or the original scan was 
re-reviewed by a radiologist. An original scan was not available in 5 CPA patients, but all 5 
patients had the typical histology and long-lasting postoperative adrenal insufficiency of at 
least 19 month in line with an unilateral CPA. PBMAH was histopathologically defined by 
the presence of macronodular hyperplasia, whereas unilateral CPAs were specified by single 
adenomas with atrophic surrounding adrenal tissue. The decision for unilateral adrenalectomy 
(ADX) in PBMAH was based on several factors which were in most instances analyzed and 
discussed in a multidisciplinary endocrine patient board: besides imaging characteristics 
(single adenoma, multiple nodules, atrophic or hypertrophic adrenal cortex) and size 
differences of the adrenal glands, these decisions were also based on cortisol gradients during 
adrenal vein sampling 15 and uptake in iodine-131 or [123 I] iodometomidate scintigraphy 16.  
Of the 85 patients, 40 were diagnosed with PBMAH, while 45 had unilateral CPAs. 
Patients who remained without surgery based on personal choice (2 PBMAH, 2 CPA) or had 
adrenal-sparing subtotal adrenalectomies (4 PBMAH, 4 CPA) were excluded from further 
analysis. The remaining patients were divided according to surgical procedure in PBMAH 
with unilateral adrenalectomy (unilat-ADX-PBMAH, n=25), bilateral adrenalectomy (bilat-
ADX-PBMAH, n=9), or CPA with unilateral adrenalectomy (unilat-ADX-CPA, n=39).  
Clinical studies 
Epidemiologic, clinical and biochemical data were extracted from patients’ files and entered 
into an electronic data base. Information on medical history and socio-demographic 
characteristics were obtained by trained and certified staff members during a standardized 
patient interview. Moreover, the participants underwent (at least once) a standardized 
postsurgical medical examination. As part of CUSTODES, the examinations were repeated 
annually. If not mentioned otherwise, results of the last follow-up are reported. The 
examination included blood sampling, evaluation of waist-to-hip ratio and quantification of 
muscle strength and blood pressure. The latter was measured three times on both arms in 
seated position after 5 minutes of rest. The mean of three measurements was used for 
statistical analysis. Grip strength was assessed with the Jamar hydraulic hand dynamometer 
(Sammons Preston, Rolyan). Mean values of three trials of the leading hand were calculated 
and compared to median values of an age- and gender-matched normative population 17. For 
the chair rising test, the time for rising from a chair (height of 45 cm) five times at maximum 
speed was taken. The patient started while seated and ended while standing. Blood samples 
were taken in the morning from fasting, seated subjects. 
The study was approved by the local ethical committees (Ethikkommission bei der 
Medizinischen Fakultät der LMU München, Ethikkommission bei der Medizinischen 
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committee of the S. Orsola-Malpighi Hospital of Bologna) and all patients provided written 
informed consent. 
Biochemical measurements 
24 hours urinary free cortisol (UFC) was measured with the Liaison Assay (DiaSorin) or with 
RIA (Immunotech-Assay, Beckman-Coulter). ACTH and serum cortisol were measured with 
the Liaison Assay (DiaSorin) or with Immulite (Siemens Healthineers). All other biochemical 
variables were assayed in the central laboratories of the participating centers, using 
standardized analytical methods.  
Definitions 
Subjects with blood pressure ≥ 140/90 mmHg, self-reported history of hypertension or intake 
of antihypertensive medication were classified as hypertensive. Diabetes was defined by 
HbA1c levels ≥ 6.5% or treatment with antidiabetic drugs. Osteoporosis was defined by T-
values ≤-2.5 SD using dual energy X-ray absorptiometry (DXA). Cushing’s stigmata 
included a large variety of symptoms regarded as disease-specific (e.g. moon face, buffalo 
hump, hirsutism or skin alterations). Muscle weakness was defined by the self-reported 
disability to rise from knee bending without the aid of arms. Psychiatric morbidities included 
self-reported anxiety, depression, panic attacks or psychosis. Clinical remission of CS was 
defined by the disappearance of Cushing’s stigmata. Biochemical remission from CS was 
defined by dependence on glucocorticoid substitution and/or normalization of dexamethasone 
suppressed serum cortisol (<1.8 µg/dl) and/or normal urinary free cortisol excretion (< 
150µg/24h).  
Genetic testing 
Genetic testing was performed, as previously described 18. The ARMC5 coding sequence as 
well as flanking intronic sequences were amplified by PCR from leukocyte DNA of 11 
patients. Both strands of the amplified products were directly sequenced with forward and 
reverse primers. All mutations were confirmed twice in two independent experiments. The in 
silico software Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/) and SIFT version 2 
(http://sift.jcvi.org/www/SIFT_enst_submit.html) was utilized to predict the pathogenic 
potential of the missense variants. The software Mutalyser (Version 2.0.3; 
https://mutalyzer.nl/name-checker/) was utilized to check the sequence variant nomenclature 
according to Human Genome Variation Society version 2.0. 
Quality of life questionnaires 
A generic health-related quality of life (QoL) questionnaire (SF-36 Health Survey) 19 and two 
disease-specific instruments (Tuebingen CD-25 20 and Cushing QoL 21) were used for the 
assessment of QoL. In each of these questionnaires, values can range from 0 to 100. Higher 
scores in the SF-36 Health Survey as well as the Cushing QoL and lower scores in the 
Tuebingen CD-25 indicate better QoL.  
Statistical analysis 
Data were extracted from the German Cushing’s Registry CUSTODES. If not stated 
otherwise, results are expressed as median and interquartile range (IQR). Data between 
groups were compared using χ2-Test (2-sided), Mann-Whitney U test or Kruskal-Wallis test. 
Survival was analyzed using Kaplan-Meier curves. Concerning health-related QoL, Mann 
Whitney U test was used for comparison of scores between different patient groups. P<0.05 
was considered statistically significant. Statistical analysis was performed using SPSS vers. 
25 (IBM). 
RESULTS 
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As summarized in Table 1, clinical and biochemical parameters at initial diagnosis of 
Cushing’s syndrome were comparable between unilat-ADX-PBMAH, bilat-ADX-PBMAH 
patients and patients with unilat-ADX-CPA except for age at diagnosis. Two out of 10 tested 
PBMAH patients were found to carry ARMC5 mutations. 
Initial clinical and biochemical outcome following 1st surgery 
Unilateral adrenalectomy resulted in clinical and biochemical remission in 21 of the 25 (84%) 
PBMAH patients. As to be expected, 100% of the bilat-ADX-PBMAH patients and the 
unilat-ADX-CPA experienced clinical and biochemical remission (Table 2).  
Persistence and recurrence of Cushing’s syndrome 
Adrenalectomy of the contralateral side had to be performed in 3 (12%) of the PBMAH 
patients initially subjected to unilateral adrenalectomy because of persistent or recurrent 
hypercortisolism. One patient of the bilat-ADX-PBMAH group developed a (clinically silent) 
para-aortic tumor 20 years after BADX. This lesion was incidentally detected during CT 
imaging for a suspected renal carcinoma and surgically resected because of the suspicion of a 
lymph node metastasis. Histology demonstrated an adrenal marconodule. 
Standardized clinical and biochemical evaluation at last follow-up 
After a median follow-up of 50 months, 96% of the unilaterally adrenalectomized PBMAH 
patients were clinically controlled, defined by remission of Cushing’s stigmata. In contrast, 
the percentage of biochemically controlled patients was lower, with 67% having normalized 
24h urinary free cortisol (UFC) and 32% having normal cortisol suppression after 1mg 
dexamethasone. UFC was 1.1-fold the upper limit of normal (= 10% above the reference 
range) in unilat-ADX-PBMAH (n=13) compared to 0.5-fold in unilat-ADX-CPAs (n=28, 
p<0.001).  
Table 3 summarizes clinical and biochemical parameters at follow-up examination in the 
three patient groups after exclusion of patients who underwent second ADX (n=3) or were 
lost to follow-up (n=3). According to this analysis, unilat-ADX-PBMAH patients were 
characterized by elevated midnight salivary cortisol and pathologic dexamethasone 
suppression test. Clinical outcome was not significantly different compared to bilat-ADX-
PBMAH patients and unilat-ADX-CPA patients except for systolic blood pressure.  
Adrenal insufficiency and adrenal crisis 
Out of 20 unilat-ADX-PBMAH patients 10 (50%) suffered from temporary and 1 (5%) from 
persistent adrenal insufficiency, while the remaining 9 patients (45%) never experienced 
adrenal insufficiency (Figure 1). Expectedly, all patients with unilat-ADX-CPA developed 
adrenal insufficiency (58% temporary and 42% persistent at last follow-up) and all bilat-
ADX-PBMAH patients remained adrenal insufficient. Duration of temporary adrenal 
insufficiency was significantly shorter in unilat-ADX-PBMAH patients compared to patients 
with unilat-ADX-CPA (median 3 months (IQR 6) vs. 19 months (IQR 45), p=0.002). The 
daily hydrocortisone replacement dose at last follow-up was not significantly different 
between bilat-ADX-PBMAH patients and unilat-ADX-CPA patients (median 25mg/d (IQR 
15) vs. 20mg/d (IQR 9), p=ns). None of the unilat-ADX-PBMAH patients experienced an 
adrenal crisis, whereas 38% of the bilat-ADX-PBMAH patients and 8% of the unilat-ADX-
CPA patients had one crisis per year on average (p=0.009).  
Quality of Life and psychiatric morbidity  
QoL at last follow-up was not significantly different between the 3 patient groups except for 
general health and vitality in the SF-36 questionnaire, which was lowest in the unilat-ADX-
CPA patients (Table 4). Similarly, psychiatric morbidity was higher in unilat-ADX-CPA 
patients (39% vs. 16% in unilat-ADX-PMAH and 0% in bilat-ADX-PBMAH).  
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Surgical 30 day mortality was 0% in all groups. During follow-up, 3 out of the 20 unilat-
ADX-PBMAH patients (15%) died. Causes for death were septic shock, sepsis with cardiac 
decompensation and sudden death of unknown cause (each n=1). All 3 patients had persisting 
biochemical hypercortisolism at last follow up. In the other two groups (bilat-ADX-PBMAH 
and unilat-ADX-CPA) no patient died (Figure 2, p=0.008). The last available cortisol level 
after 1mg dexamethasone was significantly higher in the unilat-ADX-PBMAH patients who 
died than in surviving patients (15.6 vs. 2.4µg/dl, p=0.014).  
DISCUSSION 
An increasing number of studies reported on unilateral adrenalectomy in PBMAH patients 9-
13,22,23. These data suggest that unilateral ADX is a safe procedure, which controls 
hypercortisolism and avoids the risks implied by persistent adrenal insufficiency. However, 
several caveats have to be taken into account. The number of patients studied is still limited 
to 7 studies with a total of 81 patients, and most reports were based on monocentric series. 
Moreover, there are no reference patient groups and long-term mortality has not been 
reported. These limitations prompted our study, which is multicentric and provides long-term 
follow-up on important clinical, biochemical and health related quality of life parameters. In 
addition, the data are compared with outcome data of a closely related entity, cortisol 
producing adenomas. In terms of severity of Cushing’s syndrome at time of diagnosis, our 
cohorts were well balanced with respect to BMI, blood pressure, diabetes, and biochemical 
parameters of hypercortisolism. 
Novelties of the current analysis 
Our study provides substantial new information relevant to patients and physicians. Firstly, 
clinical outcome data of our series demonstrate that unilateral adrenalectomy in PBMAH 
patients results in long-term control of Cushing stigmata similar to both control groups, 
bilaterally adrenalectomized PBMAH patients and unilaterally adrenalectomized CPA 
patients. Secondly, compared to both control groups, the outcome in unilaterally 
adrenalectomized PBMAH is -grosso modo- similar with respect to metabolic, 
cardiovascular, health-related QoL, and musculoskeletal parameters. Thirdly, however, a 
substantial percentage of unilat-ADX-PBMAH patients - in our series 33% (UFC) to 68 % (1 
mg dexamethasone test) - keep or re-develop the endocrine phenotype of excessive cortisol 
secretion. Within this cohort we observed three premature casualties, in part due to infectious 
complications, which might be interpreted as an indicator of impaired immune function due 
to hypercortisolism. These patients had less controlled cortisol levels compared to the 
patients who were still alive at last follow-up.  
Outcome of PBMAH in comparison to published series 
84% of the unilat-ADX-PBMAH patients in our cohort experienced initial remission. 
Remission rates previously reported are similar while the overall variability is large (25-93%) 
9-11,13. Contralateral adrenalectomy was performed in 12% of our initially unilaterally 
adrenalectomized PBMAH patients at a later stage, compared to 0-33% in the literature 9-13.  
In contrast to clinical outcome, biochemical outcome was less successful in our series as 
only 67% had normalized UFC or received glucocorticoid replacement after a median follow-
up of 42 months. Normalization of UFC was superior in 2 studies with 86% and 93% after a 
median follow-up of 53 months and 69 months, respectively 11,13. Debillon showed 
normalization of UFC in all cases 3 months postoperatively, but elevation of UFC after 8 
years in 13% 10. Thus, it has to be taken into account that elevation of UFC might re-occur at 
a later stage after adrenalectomy. In accordance with Lamas 12, we recognized elevated 
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79% and 67% of cases, respectively. Importantly, abnormalities in circadian cortisol rhythm 
have been associated with increased risk of cardiovascular morbidity 24.  
Occurrence of adrenal insufficiency was similar to the rates in published data. Of the 
unilat-ADX-PBMAH patients 50% had temporary, and 5% persistent adrenal insufficiency, 
whereas 45% never experienced adrenal insufficiency. In the literature, the frequencies of 
adrenal insufficiency range from 7 to 50% (temporary), from 0 to 33% (persistent) and from 
50 to 71% (absent) 10-12. Of note, 38% of the bilat-ADX-PBMAH patients in our series had 
one adrenal crisis per year on average. On the other hand, long-term outcomes of bilateral 
adrenalectomy in Cushing’s syndrome patients have been shown to be favorable 25.  
Postoperative QoL in the SF-36 questionnaire was comparable to the postoperatively 
improved values of unilat-ADX-PBMAH patients reported by Iacobone 11. 
Although severity and duration of hypercortisolism before surgery as well as 
comorbidities were comparable between uni- and bilateral adrenalectomized PBMAH 
patients and unilateral adenoma patients, mortality was significantly different. In the group of 
unilaterally adrenalectomized PBMAH patients 3 died, whereas in the other two groups no 
death occurred. In the literature mortality has not been reported, especially not compared to 
other adrenal Cushing entities or different treatment options as bilateral adrenalectomy. We 
believe that our data indicate that unilaterally adrenalectomized PBMAH patients, while 
being clinically asymptomatic, are at sustained risk for adverse outcome especially when 
biochemical parameters of autonomous cortisol secretion are greatly elevated. 
Strengths and limitations  
The strengths of our study include the multicentric approach, the large number of subjects, 
the systematic evaluation of Cushing associated comorbidities, and the long follow-up 
allowing a mortality analysis. The limitations are largely related to the retrospective study 
design: individual decisions for unilateral or bilateral adrenalectomy did not follow a pre-
defined protocol. Some patients were lost to follow-up, and standardized evaluation of 
outcomes was only possible in a subgroup of patients. Moreover, the group of bilaterally 
adrenalectomized PBMAH patients was much smaller than the group of unilaterally 
adrenalectomized PBMAH patients. However, considering the exceptional rarity of this 
condition, we are convinced that the presented data are robust enough to justify our 
conclusions. 
Conclusions 
The present study provides rare data of long-term outcome and mortality of PBMAH patients 
after adrenalectomy in comparison with a reference patient group. Argumentation for 
acceptance of mild persistent hypercortisolism against lifelong glucocorticoid dependence is 
justifiable – as long as it does not lead to enhanced mortality. In view of the presented data, 
unilateral adrenalectomy should be used with reservation and should be reserved for PBMAH 
patients with asymmetric hyperplasia or mild cortisol secretion 11. Although our observational 
data do not allow to define a ‘safe’ urinary free cortisol cut-off we believe that persistently 
elevated levels of more than 2 times upper limit of the norm should lead to additional 
measures to control hypercortisolism, such as adrenostatic treatment or (subtotal) 
contralateral adrenal surgery. 
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Figure 1: Kaplan–Meier analysis on adrenal insufficiency for PBMAH patients after 
unilateral (unilat-ADX-PBMAH, n=11) or bilateral adrenalectomy (bilat-ADX-PBMAH, 











































































































































































The Journal of Clinical Endocrinology & Metabolism; Copyright 2019  DOI: 10.1210/jc.2018-02204 
 
 10
Figure 2: Kaplan–Meier analysis on overall survival for PBMAH patients after unilateral 
(unilat-ADX-PBMAH, n=20) or bilateral adrenalectomy (bilat-ADX-PBMAH, n=9) and 
patients with cortisol-producing adenoma after unilateral adrenalectomy (unilat-ADX-CPA, 
n=38). 
Table 1: Clinical and biochemical parameters at diagnosis of Cushing’s syndrome (CS) 
according to the underlying pathology and surgical treatment 
  
         unilat-ADX-
PBMAH         (n=25) 





Females / males 16 / 9   5 / 4  35 / 4  
 median (IQR), n median (IQR), n  median (IQR), n p 
Age at diagnosis in years 56 (22), 25 53 (35), 9 45 (19), 39 0.026 
Time from first symptoms to diagnosis 
in months 
22 (27), 15 39 (69), 7 27 (40), 37 ns 
Biochemistry     
HbA1c (%) 5.8 (0.7), 19 5.9, 2 5.6 (1.4), 19 ns 
UFC (µg/24h) 274 (299), 23 182 (1418), 6 250 (422), 26 ns 
Serum cortisol after 1mg DXM (µg/dl) 9 (12), 23 15 (239), 5 15 (16), 33 ns 
Midnight salivary cortisol (µg/l) 4 (5), 10 11, 1 4 (6), 21 ns 
ACTH (pg/ml) 2.5 (5.0), 21 2.5 (2.5), 7 3.0 (2.9), 27 ns 
Clinical evaluation      
Systolic blood pressure (mmHg) 140 (25), 21 140 (43), 5 145 (32), 29 ns 
Diastolic blood pressure (mmHg) 88 (11), 21 100 (15), 5 90 (20), 29 ns 
BMI (kg/m2) 27 (8), 22 27 (5), 5 29 (10), 33 ns 
 %, n %, n %, n p 
Prevalence of Cushing’s stigmata 68, 22 86, 7 80, 35 ns 
unilat-ADX-PBMAH, unilaterally adrenalectomized PBMAH; bilat-ADX-PBMAH, bilaterally 
adrenalectomized PBMAH; unilat-ADX-CPA,  unilaterally adrenalectomized CPA; PBMAH, Primary bilateral 
macronodular adrenocortical hyperplasia; CPA, cortisol producing adenoma; UFC, urinary free cortisol; DXM, 
dexamethasone; BMI, body mass index. Conversion from ACTH in pg/mL to SI units (pmol/L) is performed by 
multiplication by 0.22 
Table 2: Clinical and biochemical outcomes in patients with PBMAH after uni- or bilateral 
adrenalectomy (unilat-ADX-PBMAH and bilat-ADX-PBMAH) and patients with CPA after 
unilateral adrenalectomy (unilat-ADX-CPA) 
 unilat-ADX-
PBMAH n (%)  
bilat-ADX-
PBMAH n (%)  
unilat-ADX-CPA n (%)  p 
Initial remission  21/25 (84) 9/9 (100) 39/39 (100) 0.017 
Recurrence 3/21 (14) 1/9 (11)* 0/39 (0) ns 
2nd operation necessary 3/25 (12) 1/9 (11)* 0/39 (0) ns 
Remission at last FU (acc. to definition)     
- clinically controlled  22/23 (96) 8/9 (89) 28/38 (74) ns 
- biochemically controlled (UFC) 12/18 (67) 9/9 (100) 30/31 (97) 0.004 
- biochemically controlled (DXM) 7/22 (32) 9/9 (100) 30/31 (97) 0.000 
* 1992 BADX, 2012 removal of a suspicious partaaortal lymphnode, histologically being an adrenal adenoma  
PBMAH, Primary bilateral macronodular adrenocortical hyperplasia; CPA, cortisol producing adenoma; FU, 
follow-up. Definition: clinically controlled was defined by the remission of Cushing stigmata; biochemically 
controlled was defined by dependence on glucocorticoid substitution and urinary free cortisol (UFC) <150µg/d 
or cortisol after 1mg dexamethasone (DXM) < 1.8µg/dl. 
Table 3: Clinical and biochemical outcome in patients with PBMAH after uni- or bilateral 
adrenalectomy (unilat-ADX-PBMAH and bilat-ADX-PBMAH) and patients with CPA after 
unilateral adrenalectomy (unilat-ADX-CPA) at last follow-up 
 unilat -ADX-PBMAH  (n=20) bilat -ADX-




Females / males 14 / 6 5 / 4 34 / 4 0.039 
 median (IQR), n median (IQR), n median (IQR), n p 
Age at last follow-up in years 65 (11), 20 65 (29), 9 55 (24), 38 0.011 
Follow-up time since operation in months 50 (100), 20 88 (164), 9 55 (107), 38 ns 










































































































































































The Journal of Clinical Endocrinology & Metabolism; Copyright 2019  DOI: 10.1210/jc.2018-02204 
 
 11
UFC (µg/24h) 117 (133), 13 35, 3 41 (62), 28 0.003 
Serum cortisol after 1mg DXM (µg/dl) 2.6 (3.1), 18 0.5, 3 1.0 (0.3), 17 0.000 
Midnight salivary cortisol (µg/l) 2.1 (2.3), 8 2.2, 2 0.8 (1.0), 29 0.016 
ACTH (pg/ml) 15 (11), 19 13 (38), 8 20 (14), 38 ns 
Clinical evaluation at follow-up     
Systolic blood pressure (mmHg) 140 (20), 19 135 (26), 9 119 (26), 38 0.011 
Diastolic blood pressure (mmHg) 81 (16), 19 80 (13), 9 78 (12), 38 ns 
HbA1c (%) 5.8 (0.8), 19 5.7 (0.9), 8 5.6 (0.6), 38 ns 
Total cholesterol (mg/dl) 207 (59), 19 208 (83), 8 200 (47), 38 ns 
LDL (mg/dl) 112 (42), 19 122 (45), 7 114 (45), 38 ns 
Triglycerides (mg/dl) 94 (84), 19 151 (143), 8 129 (105), 37 ns 
Lowest T-value in DXA -1.7, 3 -0.5, 3 -1.2 (1.6), 23 ns 
BMI (kg/m2) 25.4 (8.6), 20 24.8 (5.7), 9 27.6 (12.0), 38 ns 
Waist-to-hip ratio 0.9 (0.1), 9 1.0, 3 0.9 (0.2), 35 ns 
Grip strength (%)* 
96 (29), 10 100 (29), 6 90 (38), 35 ns 
Chair rising test (sec.) 8 (5), 8 9 (5), 6 8 (4), 32 ns 
* Grip strength was assessed with a hand dynamometer; mean values of three trials of the leading hand were 
compared to median values of an age- and gender-matched normative population (=100%).  
PBMAH,  Primary bilateral macronodular adrenocortical hyperplasia; CPA, cortisol producing UFC; urinary 
free cortisol; DXM, dexamethasone; DXA, dual energy X-ray absorptiometry; BMI, body mass index 
Table 4: Health-related quality of life (QoL) at last follow-up in patients with PBMAH after 
uni- or bilateral adrenalectomy (unilat-ADX-PBMAH and bilat-ADX-PBMAH) and patients 
with CPA after unilateral adrenalectomy (unilat-ADX-CPA) at last follow-up 
Females and males unilat-ADX-PBMAH  bilat -ADX-PBMAH  unilat -ADX-CPA  
 median (IQR), n median (IQR), n  median (IQR), n p 
SF-36 Physical functioning 78 (58), 6 88 (35), 4 68 (41), 18 ns 
SF-36 Role-physical 63 (100), 6 88 (81), 4 0 (63), 18 ns 
SF-36 Bodily-pain 61 (51), 6 63 (36), 4 44 (56), 18 ns 
SF-36 General health 40 (30), 6 68 (30), 4 33 (26), 18 0.032 
SF-36 Vitality 45 (39), 6 58 (19), 4 28 (28), 18 0.031 
SF-36 Social functioning 57 (34), 6 94 (31), 4 38 (56), 18 ns 
SF-36 Role-emotional 33 (75), 6 84 (59), 4 50 (100), 18 ns 
SF-36 Mental health 50 (28), 6 86 (25), 4 52 (40), 18 ns 
     
Cushing QoL 64 (52), 6 79 (35), 4 44 (24), 18 ns 
     
Tuebingen CD-25 Total Score 22 (34), 6 15, 3 33 (30), 17 ns 
 n (%) n (%) n (%) p 
Psychiatric morbidity  3/19 (16)   0/9 (0) 15/38 (39) 0.042 
PBMAH, Primary bilateral macronodular adrenocortical hyperplasia; CPA, cortisol producing adenoma; SF-36, 
Short Form (36) Health Survey: higher scores indicate better QoL; Cushing QoL: higher scores indicate better 
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